ÄϹ¬28NGÏàÐÅÆ·ÅÆÁ¦Á¿

ÄϹ¬(28NG¡¤¹ú¼Ê)¹Ù·½ÍøÕ¾-ÏàÐÅÆ·ÅÆÁ¦Á¿
ÎÒÃǵķþÎñ

×÷ΪÖйúµÚÈý·½¼ì²âÓëÈÏÖ¤·þÎñµÄ¿ªÍØÕߺÍÁìÏÈÕß £¬NG28ÄϹ¬28NGÏàÐÅÆ·ÅÆÁ¦Á¿¼ì²âΪȫÇò¿Í»§Ìṩһվʽ¼ìÑé¡¢²âÊÔ¡¢Ð£×¼¡¢ÈÏÖ¤¼°¼¼Êõ·þÎñ¡£

ÄϹ¬(28NG¡¤¹ú¼Ê)¹Ù·½ÍøÕ¾-ÏàÐÅÆ·ÅÆÁ¦Á¿
ÐÐÒµ½â¾ö·½°¸

·þÎñÄÜÁ¦ÒÑÈ«ÃæÁýÕÖµ½·ÄÖ¯·þ×°¼°Ð¬°ü¡¢Ó¤Í¯Íæ¾ß¼°¼Ò¾ÓÉú»î¡¢µç×ÓµçÆ÷¡¢Ò½Ñ§½¡¿µ¡¢Ê³Æ·¼°Å©²úÎï……µÈÐÐÒµµÄ¹©Ó¦Á´ÉÏÏÂÓΡ£

ÄϹ¬(28NG¡¤¹ú¼Ê)¹Ù·½ÍøÕ¾-ÏàÐÅÆ·ÅÆÁ¦Á¿
ÌØÉ«·þÎñ

È«Ãæ±£ÕÏÆ·ÖÊÓëÄþ¾² £¬Íƶ¯ºÏ¹æÓ봴Р£¬ÕÃÏÔÆ·ÅƾºÕùÁ¦ £¬ÊµÏÖ¸ü¸ßÖÊÁ¿¡¢¸ü½¡¿µ¡¢¸üÄþ¾²¡¢¸üÂÌÉ«µÄ¿ÉÁ¬ÐøÉú³¤¡£

¼ÓÈëÎÒÃÇ
È˲ÅÕþ²ß
ÕÐÏÍÄÉÊ¿
ÄϹ¬(28NG¡¤¹ú¼Ê)¹Ù·½ÍøÕ¾-ÏàÐÅÆ·ÅÆÁ¦Á¿
È˲ÅÕþ²ß
±£ÕÏÔ±¹¤»ù±¾È¨ÒæÓ븣Àû£»Ìṩרҵ¼¼ÄÜÅàѵ £¬´Ù½øÔ±¹¤Éú³¤£»¿ªÕ¹¸»ºñ¶à²ÊµÄ»î¶¯ £¬Æ½ºâÔ±¹¤ÊÂÇéÓëÉú»î¡£
ÄϹ¬(28NG¡¤¹ú¼Ê)¹Ù·½ÍøÕ¾-ÏàÐÅÆ·ÅÆÁ¦Á¿
ÕÐÏÍÄÉÊ¿
»¶Ó­¼ÓÈëÄϹ¬28NGÏàÐÅÆ·ÅÆÁ¦Á¿¼ì²â¸÷ÈËÍ¥ £¬ÎÒÃǽ«ÎªÄã´î½¨Ò»¸ö³äʵʩչ²ÅÆø £¬ÊµÏÖÖ°ÒµÀíÏëµÄÎę̀¡£
ÄϹ¬(28NG¡¤¹ú¼Ê)¹Ù·½ÍøÕ¾-ÏàÐÅÆ·ÅÆÁ¦Á¿
ÐÂÎÅ×ÊѶ

ʹÓÃNGS¿É½øÒ»²½Ê¶±ðHer2µÍ±í´ïÈéÏÙ°©»¼ÕߵķÖ×Ó²îÒì £¬Ìá¸ß»¼Õß»ñÒæ

Ðû²¼Ê±¼ä£º2024-05-31 ä¯ÀÀ´ÎÊý£º742

       »ùÓÚÃâÒß×éÖ¯»¯Ñ§£¨IHC£©ºÍԭλÔÓ½»£¨ISH£©½á¹û £¬·ºÆðÁËÒ»ÖÖHER2µÍ±í´ïµÄÈéÏÙ°©£¨BC£©ÑÇÐÍ £¬ÆäÊýÁ¿Õ¼ËùÓÐBCµÄÒ»°ëÒÔÉÏ¡£Èç×îÐÂÖ¸ÄÏËùÇ¿µ÷µÄÄÇÑù £¬ÈËÃÇÔ½À´Ô½ÖØÊÓBCÖÐHER2µÄµÍ±í´ïÏÖÏó £¬²¢½«Æä½ç˵ΪIHC1+»òIHC2+/ISH-£¨HER2/CEP17±ÈÖµ<2.0£©¡£

        È»¶ø £¬ÎÒÃǶÔÓÚHER2-lowÈéÏÙ°©µÄʶ±ð¿ÉÄÜ´æÔÚ·ÖÆç¡£×î½ü £¬Óб¨µÀչʾÁ˲¡Àíѧ¼ÒÃÇʹÓÃÃâÒß×黯¶Ô HER2 ½øÐÐÆÀ·ÖµÄ¶à»ú¹¹ÆÀ¹À½á¹û£ºÊ¹ÓÃ4ÀàHER2 IHCÆÀ·ÖϵͳÊӲ쵽µÄÖмäÀà±ð£¨IHC1+ºÍIHC2+£©´æÔÚʵÖÊÐÔ²îÒì £¬Ò»ÖÂÐÔ·Ö±ðСÓÚ1%ºÍ3.6%¡£Í¬Ê± £¬ÔÚIHC ÆÀ·ÖΪ0µÄÑù±¾ÖвîÒìÒ²ºÜ´ó £¬×ÜÌåÒ»ÖÂÐÔ½öΪ25%¡£Òò¼ø±ðHER2 IHCÆÀ·Ö0ºÍ1+Ö±µ½×î½ü²Å¾ßÓÐÁÙ´²ÒâÒå £¬¶øÈ·ÈÏHER2 IHC 0 µ½ 1+ Ö®¼äµÄãÐÖµÊÜÈËΪÒòËØµÄÓ°Ïì £¬¿ÉÄܻᵼÖ¶ÔÇкÏHER2µÍ±í´ï°ÐÏòÖÎÁÆÌõ¼þµÄ»¼ÕßµÄʶ±ðЧ¹û²»¼Ñ¡£

        ±¾Ñо¿ÊǶÔHER2µÍ±í´ïÖ×Áö½áºÏNGS±íÕ÷µÄ¿´·¨ÑéÖ¤¡¢»Ø¹ËÐÔÑо¿ £¬Ê¹ÓÃNGSÆÀ¹ÀÒѽÓÊÜͨÀý IHC ER¡¢PR¡¢Ki67 ºÍHER2 ±í´ï¼ì²âÈéÏÙ°©Ñù±¾µÄERBB2»ùÒòÀ©Ôö¡£Í¬Ê±ÖØµã¹Ø×¢ÁËNGS·ÖÎöµÄЧÁ¦ £¬Ê¶±ðÆäËû¾ßÓÐÁÙ´²ÒâÒåµÄ·Ö×Ӱбê £¬°üÂÞESR1¡¢PIK3CA¡¢AKT1¡¢ERBB2¡¢TP53¡¢BRCA1ºÍBRCA2¡¢CNVÒÔ¼°MSI¡£

 

ÄϹ¬(28NG¡¤¹ú¼Ê)¹Ù·½ÍøÕ¾-ÏàÐÅÆ·ÅÆÁ¦Á¿


±³ ¾°
        ºÍ¼¤ËØÊÜÌ壨HR£©¡¢´Æ¼¤ËØ£¨ER£©ºÍÔм¤ËØÊÜÌ壨PR£©±í´ïÒ»Ñù £¬HER2±í´ï״̬ҲÊÇÈéÏÙ°©£¨BC£©Õï¶ÏµÄ³ß¶È¡£µ±Ê¹ÓÃÃâÒß×黯£¨IHC£©½øÐÐÆÀ¹Àʱ £¬Æ¾¾ÝȾɫǿ¶È¡¢HER2ÑôÐÔÖ×Áöϸ°ûµÄ°Ù·Ö±È £¬ÒÔ0ÖÁ3+µÄÆ·¼¶¶ÔERBB2»ùÒò±àÂëµÄHER2ÂѰ׵ıí´ï½øÐÐÆÀ·Ö¡£ÔÚHER2 2+µÄÇé¿öÏ £¬Ê¹ÓÃԭλÔÓ½»£¨ISH£©¼ì²âHER2»ùÒòµÄÀ©Ôö¡£×÷Ϊ²Î¿¼ £¬½øÐÐ17ºÅȾɫÌå×ÅË¿Á££¨CEP17£©µÄ±êÖ¾ £¬µ±¼ì²âµ½¸ßˮƽµÄ»ùÒòÀ©Ôö£¨ERBB2/CEP17 ±ÈÖµ > 2.0£©Ê± £¬½ç˵Ö×ÁöΪISHÑôÐÔ¡£

        ÈçÏÂͼËùʾ £¬HER2ÑôÐÔ״̬½ç˵Ϊǿ£¨3+£©IHC¹ý±í´ï»òÖеȣ¨2+£©IHC¹ý±í´ïͬʱ»ùÒòÀ©Ôö£¨ISH+£©¡£10%-20%µÄBCΪHER2ÑôÐÔ £¬HER2ÑôÐÔBC»¼Õ߿ɽÓÊÜÕë¶ÔHER2ÂѰ׵İÐÏòÖÎÁÆ £¬Èçµ¥¿Ë¡¿¹ÌåÇúÍ×Öéµ¥¿¹ºÍÅÁÍ×Öéµ¥¿¹¡¢¼¤Ã¸ÒÖÖÆ¼ÁÀ­ÅÁÌæÄá £¬ÒÔ¼°¿¹Ìå-Ò©ÎïżÁªÎï £¨ADC£©µÂÇúÍ×Öéµ¥¿¹¡£

 

ÄϹ¬(28NG¡¤¹ú¼Ê)¹Ù·½ÍøÕ¾-ÏàÐÅÆ·ÅÆÁ¦Á¿

 

ÒªÁìѧ

        ´ÓÂåÁÖ°©Ö¢Ñо¿ËùµÄ»ú¹¹Ö×Áö¿âÖÐÈë×éÁË31¸öFFPE BCÖ×Áö±ê±¾£»½«Ö×ÁöÀιÌÔÚ 4% »º³å¼×ȩˮÈÜÒºÖÐÖÁÉÙ 12 Сʱ£¨»î¼ì£©»ò24Сʱ£¨ÊÖÊõ±ê±¾£© £¬È»ºó°üÂñʯÀ¯¡£½ÓÄÉÃâÒß×黯·¨¼ì²âCK19¡¢´Æ¼¤ËØÊÜÌ壨ER£©¡¢Ôм¤ËØÊÜÌ壨PR£©¡¢HER2ºÍKi-67µÄ±í´ï¡£

        Ê¹Óö¨ÖÆÉè¼ÆµÄ¡¢»ùÓÚ²¶×½µÄ“¹ÌÌåÖ×ÁöÈÜÒº”ÊÔ¼ÁºÐ£¨Sophia Genetics £¬Geneva £¬Switzerland£©´Ó100ngÌáÈ¡µÄÖ×ÁöDNAÖÆ±¸NGSÎĿ⠣¬¸ÃÊÔ¼ÁºÐº­¸ÇÁË51¸ö°©Ö¢Ïà¹Ø»ùÒòµÄÁÙ´²¹Ø×¢ÇøÓò £¬ÆäÖаüÂÞBC·Ö×ӰлùÒò £¬ÈçESR1¡¢PIK3CA¡¢AKT1¡¢ERBB2¡¢TP53¡¢BRCA1ºÍBRCA2¡£Ê¹ÓÃMiSeq²âÐòÒÇ£¨Illumina£©½øÐаÐÏò²âÐò¡£

 

½á   ÂÛ

        ÔÚÒ»ÏßIHCͨÀý·ÖÎöÖ®ºó £¬NGS¿ÉÒÔÌṩ¶à¸öÉúÎï±êÖ¾ÎïÐÅÏ¢¼°MSI״̬ £¬´Ó¶øÊ¹HER2-lowºÍTNBC»¼Õß»ñÒæ £¬²¢Í¬Ê±½ÚÊ¡ÁËÑù±¾ÖÊÁϺÍʱ¼ä¡£

 

½á¹û 1£ºKi67±í´ïÔÚHer2+µÄÈéÏÙ°©Ñù±¾ÖÐÏÔÖøÉý¸ß £¬NGSÓëFish½á¹û¾ßÓÐÒ»ÖÂÐÔ¡£

        ´ó¶àÊýÖ×ÁöΪ¼¤ËØÊÜÌåÑôÐÔ£¨29/31£© £¬½ç˵Ϊ ER£¨23/31£©»ò PR£¨23/31£©±í´ïÑôÐÔ¡£ËùÓÐÖ×ÁöµÄER/PR±í´ï¾ù¸ßÓÚ10%¡£

        HER2 IHC½á¹ûÏÔʾ £¬ËùÓÐ31ÀýÑù±¾ÖÐ £¬10ÀýIHC 0¡¢5Àý IHC1+¡¢9Àý IHC2+ºÍ7Àý IHC3+¡£Ê¹ÓÃISH½øÒ»²½·ÖÎö9¸öHER2 IHC2+Ö×Áö £¬ÔÚ4/9Ö×ÁöÖÐÊӲ쵽HER2À©Ôö£¨44%£©¡£ËùÓзÖÎöµÄBCÈËȺ°üÂÞ10¸öHER2ÒõÐÔ¡¢10¸öHER2µÍ±í´ïºÍ 11 ¸ö HER2 ÑôÐÔÖ×Áö¡£

KI67±êÖ¾·¶Î§Îª2-80% £¬ÈéÏÙ°©KI67±êÖ¾ÔÚHER2+£¨IHC3+»òIHC2+ºÍISH+£©ÖÐÏÔÖø¸ßÓÚHER2ÒõÐÔ£¨IHC0£©ºÍHER2µÍ±í´ï£¨IHC1+»ò IHC2+¡¢ISH-£© £¬Æ½¾ùֵΪ 34.2£¨SD = 19.2£©¡¢15.8£¨SD = 13.4£©ºÍ13.5£¨SD = 6.5£©£¨ÈçÏÂͼA£©¡£

        µ±Ê¹ÓÃNGS¼ì²â £¬HER2ÑôÐÔ¡¢HER2µÍ±í´ï¡¢HER2ÒõÐÔÖ×ÁöÖ®¼äµÄERBB2»ùÒòµÄCNVÖµÓÐÏÔÖø²îÒ죨p < 0.001£© £¬Æ½¾ùÖµ·Ö±ðΪ7.8£¨SD = 6.8£©¡¢1.9£¨SD = 0.3£©ºÍ2.0£¨SD = 0.3£©£¨ÈçÏÂͼ2B£©¡£µ± CNV µÄÁÙ½çÖµÉèÖÃΪ 3.25 ʱ £¬³ýÒ»¸öÑùÆ·£¨ÑùÆ· #24£©Íâ £¬ËùÓÐÑùÆ·µÄ ISH ºÍ NGS Ö®¼äµÄ HER2 À©Ôö״̬һÖ¡£×ÜÖ® £¬IHCÁªºÏNGS ÓëIHC ÁªºÏ ISHµÄ½á¹ûÒ»ÖÂÐÔΪ96.8%¡£

 

ÄϹ¬(28NG¡¤¹ú¼Ê)¹Ù·½ÍøÕ¾-ÏàÐÅÆ·ÅÆÁ¦Á¿

 

½á¹û 2£ºNGS½øÒ»²½¼ì²â³öÓÐÁÙ´²ÒâÒåµÄλµã¡£

        ÔÚ19%£¨6/31£©µÄ²¡ÀýÖÐ £¬HER2ÒõÐÔÖ×Áö£¨2ÀýFGFR1À©Ôö £¬2ÀýMYOD1À©Ôö£©ºÍHER2ÑôÐÔÖ×Áö£¨1ÀýFGFR1À©Ôö £¬1ÀýPIK3CAÀ©Ôö £¬1ÀýROS1À©Ôö£©Í¬Ê±¼ì²âµ½ÌرðµÄ»ùÒòÀ©Ôö¡£

        ÔÚ68%£¨21/31£©µÄ²¡ÀýÖÐ £¬ÓÐ12¸öPIK3CA¡¢6¸öTP53¡¢2¸öAKT1ºÍ4¸öBRCA2Í»±ä £¬ÔÚ51¸ö»ùÒò×éºÏÖмì²âµ½ÆäËûÖ²¡ÐԺͿÉÄܵÄÖ²¡»ùÒòÍ»±ä¡£

        ´ËÍâ £¬ÔÚЯ´øPIK3CA»ùÒòÍ»±äµÄHER2ÒõÐÔ¡¢ISHδÀ©Ôö¡¢HRÑôÐÔÖ×ÁöÖмì²âµ½Ò»ÀýMSI ״̬£¨c.1624G > A £¬p.£¨Glu542Lys£©£©¡£

 

ÄϹ¬(28NG¡¤¹ú¼Ê)¹Ù·½ÍøÕ¾-ÏàÐÅÆ·ÅÆÁ¦Á¿

ÄϹ¬(28NG¡¤¹ú¼Ê)¹Ù·½ÍøÕ¾-ÏàÐÅÆ·ÅÆÁ¦Á¿


ÌÖ   ÂÛ

        HER2µÍ±í´ïBCÕ¼HR+Ö×ÁöµÄ40%-65% £¬23-40%µÄHRÒõÐÔÖ×Áö±í´ïµÍˮƽHER2¡£HER2µÄ±í´ïÊǶ¯Ì¬µÄ £¬¶øÇÒÔ­·¢Ö×ÁöºÍÍíÆÚ¼²²¡Ö®¼äµÄת»¯ÂÊ·×ÆçÖ¡£ÕâЩ½á¹ûÇ¿µ÷ £¬ÔÚ¼²²¡½øÕ¹Ê±½øÐÐÖØ¸´Éú¼ìÊÇÓÐÓÃµÄ £¬Õâ¿ÉÄÜ»áÓ°ÏìÖÎÁÆÑ¡Ôñ¡£Æ¾¾Ý¼¤ËØÊÜÌå £¨HR£© ºÍ HER2 µÄ±í´ï £¬BCÔø¾­±»·ÖÀà·ÖΪËÄÖÖÑÇÐÍ£º¹ÜÇ» A£¨HR+ºÍ HER2-£©¡¢¹ÜÇ»B£¨HR+ºÍ HER2+£©¡¢HER2ÑôÐÔ£¨HR−ºÍHER2+£©ºÍÈýÒõÐÔBC£¨TNBC¡¢HR-ºÍHER2-£© £¬ÆäÖÐTNBCͨ³£±»ÈÏΪÊÇÔ¤ºó×î²îµÄ¡£HER2-low BCÊÇHER2ÒõÐÔÖеÄÒ»ÖÖÒìÖÊÐÔ¼²²¡ £¬ÌåÏÖ³öDESTINY-Breast04 ÈýÆÚÊÔÑé½ÒʾÁËT-DXdÔÚ¼ÈÍù½ÓÊܹýÒ»Ïß»ò¶þÏß»¯ÁƵÄ×ªÒÆÐÔÈéÏÙ°©»¼ÕßHER2-lowÖеÄÁÆÐ§ £¬ÓëÒ½ÉúÑ¡ÔñµÄ»¯ÁÆÏà±È £¬T-DXdÏÔÖøÔö¼ÓÁËPFSºÍOS¡£¶øÔÚDAISYÊÔÑéÖÐ £¬¼´Ê¹HER2±í´ïˮƽ·Ç³£µÍ £¬ËƺõÒ²ÄÜÇý¶¯T-DXdµÄϸ°ûÉãÈ¡»òÆäËû¶ÀÁ¢ÓÚHER2µÄ»úÖÆ £¬²¿ÃżÓÈëÁËT-DXdµÄÁÆÐ§¡£

        Òò´Ë £¬Ê¶±ðHER2µÍ±í´ï״̬ÔÚBCµÄ¹ÜÀíÖбäµÃÖÁ¹ØÖØÒª £¬µ«¼ì²âÒªÁìѧ¿ÉÄÜ»áÓ°Ïì HER2¡¢IHC ºÍ ISH ͨÀý¼ì²âµÄÃô¸ÐÐԺͿÉÖØ¸´ÐÔ£»Í¬Ê±Ó¦¿¼ÂÇHER2±í´ï»òÀ©ÔöµÄÒìÖÊÐÔ £¬ÒÔ¸ÄÉÆHER2µÍ±í´ïµÄʶ±ð¡£NGS¼¼ÊõµÄÉú³¤ÎªÈéÏÙ°©£¨BC£©ºÍÈýÒõÐÔÈéÏÙ°©µÄ¾«×¼Ò½ÁÆÖÎÁƼÆÄ±´øÀ´ÁËÏ£Íû¡£×î½üÔÚ¹ú¼ÊÖ¸ÄÏÖÐÔö¼ÓµÄÐ޸İüÂÞESR1»ùÒòÍ»±äºÍÄÇЩÈÔÐèÒªÑéÖ¤ÐÔǰհÐÔÑо¿µÄÍ»±ä £¬µ«ÁÆÐ§Ö¤¾Ý¿ÉÓà £¬°üÂÞ PIK3CA¡¢AKT1¡¢HER2¡¢TP53¡¢BRCA1 ¡£PIK3CAÍ»±äºÍÀ©ÔöԼĪ´æÔÚÓÚ10%µÄHRÑôÐÔºÍHER2ÒõÐÔµÄÔ­·¢ÐÔBC»¼ÕßÖÐ £¬ÆäÀ©Ôö»¼ÕߵĽá¾Ö½Ï²î¡£³ýÁËÍ»±äÖ®Íâ £¬»ùÒòÀ©ÔöµÄ¼ø¶¨Ò²Ô½À´Ô½Êܵ½¹Ø×¢¡£±¾Ñо¿Öз¢ÏÖµÄһЩÀ©Ôö¾ÍÊÇÕâÖÖÇé¿ö¡£×îºó £¬MSI ״̬¿ÉÒÔ×÷ΪÉúÎï±êÖ¾Îï £¬¼È´æÔÚÓÚTNBC £¬Ò²¼ûÓÚHER2ÒõÐÔHRÑôÐÔµÄ×ªÒÆÐÔÈéÏÙ°©»¼ÕßÖС£ÔÚÕâÖÖÇé¿öÏ £¬Ê¹ÓÃNGSͬʱ²â¶¨¶ÔÓÚÃâÒßÖÎÁƺÜÓмÛÖµ¡£

 

²Î¿¼ÎÄÏ×

Merlin JL, Husson M, Sahki N, Gilson P, Massard V, Harlé A, Leroux A. Integrated Molecular Characterization of HER2-Low Breast Cancer Using Next Generation Sequencing (NGS). Biomedicines. 2023 Nov 28;11(12):3164. doi: 10.3390/biomedicines11123164. PMID: 38137385; PMCID: PMC10740754.

ÍøÕ¾µØÍ¼